<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04354246</url>
  </required_header>
  <id_info>
    <org_study_id>CPG-02-101</org_study_id>
    <nct_id>NCT04354246</nct_id>
  </id_info>
  <brief_title>COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies</brief_title>
  <official_title>A Phase 1 Study of The Safety and Tolerability of COM902 in Subjects With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Compugen Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Compugen Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1 open label sequential dose escalation and cohort expansion study evaluating the
      safety, tolerability and preliminary clinical activity of COM902 as monotherapy in subjects
      with advanced malignancies.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 31, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The safety and tolerability of COM902 monotherapy.</measure>
    <time_frame>DLT evaluation window in the 1st cycle (21 Days).</time_frame>
    <description>Incidence of subjects with Adverse Events (AEs) as per CTCAE v5.0 and Dose-Limiting Toxicities (DLTs).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D).</measure>
    <time_frame>18 months.</time_frame>
    <description>Evaluation of preliminary antitumor activity of COM902.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To characterize the pharmacokinetic (PK) profile of COM902 as monotherapy in subjects with advanced malignancies.</measure>
    <time_frame>18 months.</time_frame>
    <description>Evaluation of parameters of COM902 exposure such as Maximum Plasma Concentration [Cmax]) of COM902.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To characterize the pharmacokinetic (PK) profile of COM902 as monotherapy in subjects with advanced malignancies.</measure>
    <time_frame>18 months.</time_frame>
    <description>Evaluation of parameters of COM902 exposure such as Area under the curve (AUC).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To characterize immunogenicity of COM902 monotherapy</measure>
    <time_frame>18 months.</time_frame>
    <description>Evaluation of anti drug antibody to COM902.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Advanced Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Lung Cancer</condition>
  <condition>Colon Cancer</condition>
  <condition>Plasma Cell Neoplasm</condition>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>COM902 Monotherapy Dose Escalation Arm.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy Dose Escalation. COM902 monotherapy administered IV every 3 weeks in sequential dose escalation Cohorts using a rules-based design. Up to 7 dose escalation cohorts may be evaluated until a maximum tolerated dose or recommended phase 2 dose is identified.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>COM902</intervention_name>
    <description>COM902 monotherapy administered IV Q3 weeks in sequential dose escalation doses in cohorts of subjects.</description>
    <arm_group_label>COM902 Monotherapy Dose Escalation Arm.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Subjects with histologically/cytologically confirmed advanced malignancy (solid tumor)
             who must have exhausted all available standard therapy; or not a candidate for
             standard therapy.

          -  Subject is able to provide written, informed consent before initiation of any study
             related procedures, and is able, in the opinion of the investigator, to comply with
             all the requirements of the study.

          -  Subject has Eastern Cooperative Oncology Group (ECOG) performance status 0-1.

        Key Exclusion Criteria:

          -  Prior treatment with a TIGIT inhibitor.

          -  Symptomatic interstitial lung disease or inflammatory pneumonitis.

          -  History of immune-related events that required immunotherapy treatment
             discontinuation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lead COM902 ClinInfo</last_name>
    <phone>â€ª+1 415 373 0781</phone>
    <email>COM902-001@cgen.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Backup COM902 ClinInfo</last_name>
    <phone>+1 415 373 0781</phone>
    <email>COM902-001@cgen.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>START Midwest.</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>COM902 Study Director</last_name>
      <phone>415-373-0781</phone>
      <email>COM902-001@cgen.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The START Center for Cancer Care.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>COM902 Study Director</last_name>
      <phone>415-373-0781</phone>
      <email>COM902-001@cgen.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 15, 2020</study_first_submitted>
  <study_first_submitted_qc>April 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2020</study_first_posted>
  <last_update_submitted>June 4, 2020</last_update_submitted>
  <last_update_submitted_qc>June 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

